 |
 |
 |
|
SOLAR 3D: A PROSPECTIVE STUDY SWITCHING TO DTG/3TC
FROM 3- OR 4-DRUG ART FOR MAINTENANCE OF VIRAL
SUPPRESSION WITH HISTORIC M184V/I MUTATION
AND PRIOR VIROLOGICAL FAILURES:
48 WEEK PRIMARY ENDPOINT RESULTS
|
|
|
48 WEEK PRIMARY ENDPOINT RESULTS
EACS 2021
G.BLICK1, E. CERRETA1, G. MANCINI1, A. COSENZA1
1Health Care Advocates International, Stratford CT USA







|
|
|
 |
 |
|
|